#Tovorafenib
LightNews LightNews
pharmsolidforms.bsky.social
Tovorafenib Solvates: Insights into Structure, Stability, and Crystallization Behavior https://www.sciencedirect.com/science/article/pii/S0022286026020892 #Solvates
August 30, 2026 at 6:38 PM
pharmsolidforms.bsky.social
Tovorafenib Solvates: Insights into Structure, Stability, and Crystallization Behavior https://doi.org/10.1016/j.molstruc.2026.147335 #Crystallization #Solvates
August 26, 2026 at 9:17 AM
gpspmagazin.bsky.social
Mit Tovorafenib wird in Deutschland erstmals ein Wirkstoff bewertet, dessen #Nutzenbewertung sich auf eine europäische Auswertung der Studien stützt.

Die #Pharmaindustrie fordert Nachbesserungen und möchte zentrale Bewertungskriterien aufweichen.

gutepillen-schlechtepillen.de/neues-eu-ver...
Neues EU-Verfahren zur Nutzenbewertung - Gute Pillen - Schlechte Pillen
Die Pharmalobby kritisiert die neue EU-Nutzenbewertung. Dabei hat sie das Verfahren selbst vorgeschlagen.
gutepillen-schlechtepillen.de
July 25, 2026 at 10:00 AM
jco-asco.bsky.social
How do pediatric phase 1 trials shape targeted therapy? By balancing efficacy with long-term safety. A new study on tovorafenib established phase 2 dosing and flagged growth suppression risks for new pediatric low-grade glioma treatments.

Read the full article: https://bit.ly/4eHA7lm
July 8, 2026 at 1:00 PM
l2plabs.bsky.social
Servier Presentations at ISPNO 2026 Highlight Neuro-Oncology Leadership and Expanding Glioma Portfolio
Two analyses of updated three-year follow-up data from the pivotal Phase 2 FIREFLY-1 study of OJEMDA® (tovorafenib) in BRAF-altered pediatric low-grade glioma will be featured in separate oral presentations Results from a survey of pediatric low-grade glioma caregivers unveiling...
dlvr.it
June 26, 2026 at 1:08 PM
ipharmaservices.bsky.social
EU har publicerat sin forsta gemensamma kliniska utvardering enligt den nya HTA-forordningen. Utvärderat lakemedel: Ojemda (tovorafenib) for pediatriskt låggradig gliom.

www.ipharmacenter.com/post/eu-laun...

#Europa #nyheter #halsa #farma #healthforall
EU Launches Era of Centralized HTA with First Joint Clinical Assessment of Ojemda | iPharmaCenter
The European Commission has published its inaugural Joint Clinical Assessment (JCA), officially activating the EU’s modernized Health Technology Assessment (HTA) framework under Regulation (EU) 2021/2...
www.ipharmacenter.com
June 25, 2026 at 4:49 PM
ipharmaservices.bsky.social
UE opublikowala swoja pierwsza wspolna ocene kliniczna w ramach nowego rozporzadzenia HTA. Oceniany lek: Ojemda (tovorafenib) w pediatrycznym glejakumozgu niskiego stopnia.

www.ipharmacenter.com/post/eu-laun...

#Europa #wiadomosci #zdrowie #farma #healthforall
EU Launches Era of Centralized HTA with First Joint Clinical Assessment of Ojemda | iPharmaCenter
The European Commission has published its inaugural Joint Clinical Assessment (JCA), officially activating the EU’s modernized Health Technology Assessment (HTA) framework under Regulation (EU) 2021/2...
www.ipharmacenter.com
June 25, 2026 at 4:49 PM
ipharmaservices.bsky.social
De EU heeft haar eerste gezamenlijke klinische beoordeling gepubliceerd onder de nieuwe HTA-verordening. Beoordeeld geneesmiddel: Ojemda (tovorafenib) voor pediatrisch laaggradig glioom.

www.ipharmacenter.com/post/eu-laun...

#Europa #nieuws #gezondheid #farma #healthforall
EU Launches Era of Centralized HTA with First Joint Clinical Assessment of Ojemda | iPharmaCenter
The European Commission has published its inaugural Joint Clinical Assessment (JCA), officially activating the EU’s modernized Health Technology Assessment (HTA) framework under Regulation (EU) 2021/2...
www.ipharmacenter.com
June 25, 2026 at 4:48 PM
ipharmaservices.bsky.social
A UE publicou a sua primeira avaliacao clinica conjunta ao abrigo do novo regulamento ATS. Medicamento avaliado: Ojemda (tovorafenib) para glioma pediatrico de baixo grau.

www.ipharmacenter.com/post/eu-laun...

#Europa #noticias #saude #farma #healthforall
EU Launches Era of Centralized HTA with First Joint Clinical Assessment of Ojemda | iPharmaCenter
The European Commission has published its inaugural Joint Clinical Assessment (JCA), officially activating the EU’s modernized Health Technology Assessment (HTA) framework under Regulation (EU) 2021/2...
www.ipharmacenter.com
June 25, 2026 at 4:48 PM
ipharmaservices.bsky.social
L'UE ha pubblicato la sua prima valutazione clinica congiunta nell'ambito del nuovo regolamento HTA. Farmaco valutato: Ojemda (tovorafenib) per il glioma pediatrico di basso grado.

www.ipharmacenter.com/post/eu-laun...

#Europa #italy #notizie #salute #farma
EU Launches Era of Centralized HTA with First Joint Clinical Assessment of Ojemda | iPharmaCenter
The European Commission has published its inaugural Joint Clinical Assessment (JCA), officially activating the EU’s modernized Health Technology Assessment (HTA) framework under Regulation (EU) 2021/2...
www.ipharmacenter.com
June 25, 2026 at 4:46 PM
ipharmaservices.bsky.social
La UE publico su primera evaluacion clinica conjunta bajo el nuevo reglamento ETS. Farmaco evaluado: Ojemda (tovorafenib) para glioma de bajo grado pediatrico.

www.ipharmacenter.com/post/eu-laun...

#Europa #spain #noticias #salud #farma
EU Launches Era of Centralized HTA with First Joint Clinical Assessment of Ojemda | iPharmaCenter
The European Commission has published its inaugural Joint Clinical Assessment (JCA), officially activating the EU’s modernized Health Technology Assessment (HTA) framework under Regulation (EU) 2021/2...
www.ipharmacenter.com
June 25, 2026 at 4:45 PM
ipharmaservices.bsky.social
Die EU hat ihre erste gemeinsame klinische Bewertung im Rahmen der neuen HTA-Verordnung veroffentlicht.

Bewertetes Arzneimittel: Ojemda (Tovorafenib) fur padiatrisches niedriggradiges Gliom.

www.ipharmacenter.com/post/eu-laun...

#Europa #germany #Nachrichten #Gesundheit #Pharma
EU Launches Era of Centralized HTA with First Joint Clinical Assessment of Ojemda | iPharmaCenter
The European Commission has published its inaugural Joint Clinical Assessment (JCA), officially activating the EU’s modernized Health Technology Assessment (HTA) framework under Regulation (EU) 2021/2...
www.ipharmacenter.com
June 25, 2026 at 4:44 PM
ipharmaservices.bsky.social
L'UE a publie sa premiere evaluation clinique conjointe dans le cadre du nouveau reglement ETS.
Medicament evalue: Ojemda (tovorafenib) pour le gliome de bas grade pediatrique.
www.ipharmacenter.com/post/eu-laun...
#Europe #france #actualite #sante #pharma
EU Launches Era of Centralized HTA with First Joint Clinical Assessment of Ojemda | iPharmaCenter
The European Commission has published its inaugural Joint Clinical Assessment (JCA), officially activating the EU’s modernized Health Technology Assessment (HTA) framework under Regulation (EU) 2021/2...
www.ipharmacenter.com
June 25, 2026 at 4:44 PM
lumanity.bsky.social
The first JCA report is out, assessing Ipsen’s tovorafenib. Our new article goes beyond the headlines to look at what it confirms and where ambiguity remains from both an operational and evidence assessment view.

Read more: lumanity.com/perspectives...

#JCA #HTA #MarketAccess
Text: View. Beyond the Headlines: Assessing the First JCA Report on Tovorafenib. Lumanity logo.
June 17, 2026 at 7:01 PM
ipharmaservices.bsky.social
De #EuropeseUnie lanceert gecentraliseerde #HTA met haar eerste gezamenlijke klinische beoordeling (#JCA) van #Ojemda (#tovorafenib) voor pediatrische hersentumoren.
www.ipharmacenter.com/post/eu-laun...
#Nieuws #Pharma #Oncologie #MarketAccess #Gezondheidszorg #Regulatory #Biotech
EU Launches Era of Centralized HTA with First Joint Clinical Assessment of Ojemda | iPharmaCenter
The European Commission has published its inaugural Joint Clinical Assessment (JCA), officially activating the EU’s modernized Health Technology Assessment (HTA) framework under Regulation (EU) 2021/2...
www.ipharmacenter.com
June 11, 2026 at 7:36 PM
ipharmaservices.bsky.social
A #UniãoEuropeia lança a ATS centralizada com a sua primeira avaliação clínica conjunta (#JCA) do #Ojemda (#tovorafenib) para tumores cerebrais pediátricos.
www.ipharmacenter.com/post/eu-laun...
#Notícias #Pharma #Oncologia #MarketAccess #Saúde #Regulamentação #Biotech
EU Launches Era of Centralized HTA with First Joint Clinical Assessment of Ojemda | iPharmaCenter
The European Commission has published its inaugural Joint Clinical Assessment (JCA), officially activating the EU’s modernized Health Technology Assessment (HTA) framework under Regulation (EU) 2021/2...
www.ipharmacenter.com
June 11, 2026 at 7:35 PM
ipharmaservices.bsky.social
L'#UnioneEuropea lancia l'HTA centralizzata con la sua prima valutazione clinica congiunta (#JCA) di #Ojemda (#tovorafenib) per i tumori cerebrali pediatrici.
www.ipharmacenter.com/post/eu-laun...
#Notizie #Pharma #Oncologia #MarketAccess #Sanità #Regolatorio #Biotech
EU Launches Era of Centralized HTA with First Joint Clinical Assessment of Ojemda | iPharmaCenter
The European Commission has published its inaugural Joint Clinical Assessment (JCA), officially activating the EU’s modernized Health Technology Assessment (HTA) framework under Regulation (EU) 2021/2...
www.ipharmacenter.com
June 11, 2026 at 7:35 PM
ipharmaservices.bsky.social
La #UniónEuropea lanza la HTA centralizada con su primera evaluación clínica conjunta (#JCA) de #Ojemda (#tovorafenib) para tumores cerebrales pediátricos.
www.ipharmacenter.com/post/eu-laun...
#Noticias #Farma #Oncología #MarketAccess #Salud #Regulatorio #Biotech
EU Launches Era of Centralized HTA with First Joint Clinical Assessment of Ojemda | iPharmaCenter
The European Commission has published its inaugural Joint Clinical Assessment (JCA), officially activating the EU’s modernized Health Technology Assessment (HTA) framework under Regulation (EU) 2021/2...
www.ipharmacenter.com
June 11, 2026 at 7:35 PM
ipharmaservices.bsky.social
L'#UnionEuropéenne lance l'ETS centralisée avec sa première évaluation clinique conjointe (#JCA) d'#Ojemda (#tovorafenib) pour les tumeurs cérébrales pédiatriques.
www.ipharmacenter.com/post/eu-laun...
#Actualités #Pharma #Oncologie #MarketAccess #Sante #Reglementation #Biotech
EU Launches Era of Centralized HTA with First Joint Clinical Assessment of Ojemda | iPharmaCenter
The European Commission has published its inaugural Joint Clinical Assessment (JCA), officially activating the EU’s modernized Health Technology Assessment (HTA) framework under Regulation (EU) 2021/2...
www.ipharmacenter.com
June 11, 2026 at 7:34 PM
ipharmaservices.bsky.social
Die #EuropäischeUnion startet die zentralisierte #HTA mit ihrer ersten gemeinsamen klinischen Bewertung (#JCA) von #Ojemda (#Tovorafenib) für pädiatrische Hirntumoren.
www.ipharmacenter.com/post/eu-laun...
#Nachrichten #Pharma #Onkologie #MarketAccess #Gesundheitswesen
EU Launches Era of Centralized HTA with First Joint Clinical Assessment of Ojemda | iPharmaCenter
The European Commission has published its inaugural Joint Clinical Assessment (JCA), officially activating the EU’s modernized Health Technology Assessment (HTA) framework under Regulation (EU) 2021/2...
www.ipharmacenter.com
June 11, 2026 at 7:34 PM
longtail-news.bsky.social
Feed: "Clinical Trials Arena"
By: Salong Debbarma on Monday, May 11, 2026
Day One concludes patient enrolment for tovorafenib’s FIREFLY-2 trial
Day One Biopharmaceuticals has concluded patient enrolment in the Phase III FIREFLY-2 trial assessing tovorafenib for pLGG.
www.clinicaltrialsarena.com
May 12, 2026 at 10:48 AM
newsen.bsky.social
Day One Biopharmaceuticals and Servier Conclude Enrollment in Phase 3 Trial for Pediatric Low-Grade Glioma Therapy#USA#Boston#Day_One_Biopharmaceuticals#Servier_Group#Tovorafenib
Day One Biopharmaceuticals and Servier Conclude Enrollment in Phase 3 Trial for Pediatric Low-Grade Glioma Therapy
Day One Biopharmaceuticals and Servier have successfully finished enrollment for the FIREFLY-2 trial, assessing tovorafenib's efficacy in pediatric low-grade gliomas. Results are anticipated by mid-2027.
third-news.com
May 8, 2026 at 12:35 PM
l2plabs.bsky.social
Day One and Servier Complete Enrollment in Pivotal Phase 3 FIREFLY-2 Trial of Tovorafenib as a Front-Line Treatment for Pediatric Low-Grade Glioma (pLGG)
FIREFLY-2 is the largest study ever conducted in front-line pLGG Trial aims to extend OJEMDA's indication beyond relapsed/refractory setting to address significant unmet need; topline data expected by mid-2027 BOSTON, May 8, 2026 /PRNewswire/ -- Day One Biopharmaceuticals, Inc., now part...
dlvr.it
May 8, 2026 at 12:32 PM
cancerletter.com
@ec.europa.eu approves Ojemda as first targeted therapy in r/r pediatric low-grade glioma regardless of BRAF alteration
https://cancerletter.com/drugs-and-targets/20260424_9b/
EU approves Ojemda as first targeted therapy in r/r pediatric low-grade glioma regardless of BRAF alteration - The Cancer Letter
The European Commission has granted conditional marketing authorization for Ojemda (tovorafenib) as monotherapy for the treatment of patients 6 months of age and older with pediatric low-grade-glioma harboring a BRAF fusion or rearrangement, or BRAF V600 mutation, who have progressed after one or more prior systemic therapies. To access this subscriber-only content please log in […]
cancerletter.com
April 27, 2026 at 7:00 PM
onclive.bsky.social
🌟 This week’s #OncFive 5⃣:

🚀 Priority review for periop EV + pembro in MIBC
💉 @fda.gov review extended for SC isatuximab in myeloma
📉 Pembro combos miss mark in frontline ccRCC
🧪 Daraxonrasib shows promise in PDAC
🌍 EC clears tovorafenib for pLGG

Learn more 🔗: www.onclive.com/view/the-onc...
The OncFive: Top Oncology Articles for the Week of 4/19 | OncLive
The FDA grants priority review to enfortumab vedotin-ejfv sBLAs in MIBC, the review period for subcutaneous isatuximab BLA in myeloma has been extended, and more.
www.onclive.com
April 25, 2026 at 11:57 PM